Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined...
Uloženo v:
| Vydáno v: | Journal for immunotherapy of cancer Ročník 7; číslo 1; s. 181 - 5 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
12.07.2019
BioMed Central Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Témata: | |
| ISSN: | 2051-1426, 2051-1426 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy.
Case presentation
We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg).
Conclusion
This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. |
|---|---|
| AbstractList | BackgroundHigh response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy.Case presentationWe report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg).ConclusionThis case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. Case presentation We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Conclusion This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. Keywords: PD-1, Immune-related adverse event, Minimal change disease, Ipilimumab, Nivolumab Abstract Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. Case presentation We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Conclusion This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy.BACKGROUNDHigh response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy.We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg).CASE PRESENTATIONWe report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg).This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE.CONCLUSIONThis case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. Case presentation We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Conclusion This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. |
| ArticleNumber | 181 |
| Audience | Academic |
| Author | Grän, Franziska Schilling, Bastian Gesierich, Anja Goebeler, Matthias Glutsch, Valerie Weber, Judith |
| Author_xml | – sequence: 1 givenname: Valerie surname: Glutsch fullname: Glutsch, Valerie organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg – sequence: 2 givenname: Franziska surname: Grän fullname: Grän, Franziska organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg – sequence: 3 givenname: Judith surname: Weber fullname: Weber, Judith organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg – sequence: 4 givenname: Anja surname: Gesierich fullname: Gesierich, Anja organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg – sequence: 5 givenname: Matthias surname: Goebeler fullname: Goebeler, Matthias organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg – sequence: 6 givenname: Bastian orcidid: 0000-0001-8859-4103 surname: Schilling fullname: Schilling, Bastian email: schilling_b@ukw.de organization: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31300044$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk9v1DAQxSNURMvSD8AFRUKquKTYjuM4F6Sq_KtUCYTgbDn2ZNerxA52dqX99sySlu5WgHJI7Lz383jmPc9OfPCQZS8puaRUireJE86qgtCmIKKqCv4kO2OkogXlTJwcfJ9m5ymtCSGUlKWU8ll2WtIS15yfZekbpDH4BPkUchOG1nmwuRtd74bNoNtce5t7tw39vOomiLmFLfRhHMBPeehynXsYVzFMzuRp520MA-QRej0hCrFf3xc0H4IP0wqiHncvsqed7hOc370X2Y-PH75ffy5uv3y6ub66LUxNyFTIilphQTaW8ZaSSgKwirVAbM3blkIj2xYoMaWQbddwWzW6EyCkaBqjed2Vi-xm5tqg12qMbtBxp4J26vdGiEulIxbdg6KUGWZbrhvBuBHQmMYSKXkpTN2yqkHWu5k1btoBrMGrR90fQY__eLdSy7BVQjCBk0LAmztADD83kCY1uGSg77WHsEmKsaquiajLEqWvH0nXYRM9tkoxUUqsVUr2oFpqvIDzXcBzzR6qrrBgigfjmBfZ5V9U-FgYnMFEdQ73jwwXB4YV6H5aJZz-5DAlx8JXhx3504r7bKGgngUmhpQidMq4Se85WILrFSVqH2Q1B1lhkNU-yGrvpI-c9_D_edjsSaj1S4gPTfu36Rcu0wMH |
| CitedBy_id | crossref_primary_10_1172_JCI156250 crossref_primary_10_1111_ajco_13387 crossref_primary_10_1186_s12882_021_02257_6 crossref_primary_10_3390_diagnostics11071187 crossref_primary_10_1016_j_therap_2023_10_010 crossref_primary_10_1016_j_cotox_2022_100362 crossref_primary_10_1002_cam4_4343 crossref_primary_10_1186_s12957_020_01933_5 crossref_primary_10_1080_0886022X_2022_2147439 crossref_primary_10_1007_s40278_019_66016_x crossref_primary_10_1016_j_ejca_2019_12_015 crossref_primary_10_1177_1078155220961553 crossref_primary_10_1177_0300060519886454 crossref_primary_10_1186_s12882_024_03494_1 |
| Cites_doi | 10.1016/0002-9343(71)90205-1 10.1016/j.ejca.2016.02.025 10.1016/j.ejca.2016.07.003 10.1186/s12882-018-0958-6 10.1016/j.ejca.2017.01.009 10.1016/j.kint.2016.04.008 10.1053/j.ajkd.2017.04.026 10.1056/NEJMoa1504030 10.1093/ckj/sfw024 10.1038/sj.ki.5000341 10.1016/j.ejca.2017.06.020 10.1016/j.ctrv.2016.02.003 10.1038/bjc.2016.358 10.1016/j.ejca.2016.07.026 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s40425-019-0655-4 |
| DatabaseName | SpringerNature - open access journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_112c2db4a9624c6e9c9d088436c7b259 PMC6626404 A593166231 31300044 10_1186_s40425_019_0655_4 |
| Genre | Journal Article Case Reports |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ADBBV ADRAZ AFKRA AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RMJ ROL RPM RSV SOJ UKHRP AAYXX AFFHD CITATION -A0 3V. ABDBF ACRMQ ADINQ ADUKV ALIPV C24 CGR CUY CVF ECM EIF NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c700t-851d6de89d24b1058ee252be0d74bb1e98bbe10c368bf94d59af6e68699ca47f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000475646900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2051-1426 |
| IngestDate | Fri Oct 03 12:35:52 EDT 2025 Tue Nov 04 01:59:29 EST 2025 Fri Sep 05 10:34:28 EDT 2025 Tue Oct 07 06:45:05 EDT 2025 Tue Nov 11 10:28:04 EST 2025 Tue Nov 04 17:56:06 EST 2025 Thu May 22 21:23:37 EDT 2025 Thu Jan 02 22:57:30 EST 2025 Sat Nov 29 03:12:24 EST 2025 Tue Nov 18 20:51:55 EST 2025 Sat Sep 06 07:27:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Minimal change disease Immune-related adverse event PD-1 Ipilimumab Nivolumab |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c700t-851d6de89d24b1058ee252be0d74bb1e98bbe10c368bf94d59af6e68699ca47f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0001-8859-4103 |
| OpenAccessLink | https://doaj.org/article/112c2db4a9624c6e9c9d088436c7b259 |
| PMID | 31300044 |
| PQID | 2638112882 |
| PQPubID | 2040222 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_112c2db4a9624c6e9c9d088436c7b259 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6626404 proquest_miscellaneous_2257706733 proquest_journals_2638112882 gale_infotracmisc_A593166231 gale_infotracacademiconefile_A593166231 gale_healthsolutions_A593166231 pubmed_primary_31300044 crossref_citationtrail_10_1186_s40425_019_0655_4 crossref_primary_10_1186_s40425_019_0655_4 springer_journals_10_1186_s40425_019_0655_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07-12 |
| PublicationDateYYYYMMDD | 2019-07-12 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | j. immunotherapy cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | L Zimmer (655_CR2) 2017; 75 FB Cortazar (655_CR4) 2016; 90 N Murakami (655_CR8) 2016; 9 MC Kirchberger (655_CR3) 2016; 65 B Gao (655_CR9) 2018; 19 V Audard (655_CR11) 2006; 69 P Kramer (655_CR12) 1981; 24 J Larkin (655_CR1) 2015; 373 S Ugurel (655_CR14) 2017; 83 L Hofmann (655_CR6) 2016; 60 J Belliere (655_CR7) 2016; 115 S Herz (655_CR15) 2016; 67 A Kitchlu (655_CR10) 2017; 70 J Plager (655_CR13) 1971; 50 TK Eigentler (655_CR5) 2016; 45 |
| References_xml | – volume: 24 start-page: 114 issue: 3 year: 1981 ident: 655_CR12 publication-title: Neth J Med – volume: 50 start-page: 56 issue: 1 year: 1971 ident: 655_CR13 publication-title: Am J Med doi: 10.1016/0002-9343(71)90205-1 – volume: 60 start-page: 190 year: 2016 ident: 655_CR6 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.02.025 – volume: 65 start-page: 182 year: 2016 ident: 655_CR3 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.07.003 – volume: 19 start-page: 156 issue: 1 year: 2018 ident: 655_CR9 publication-title: BMC Nephrol doi: 10.1186/s12882-018-0958-6 – volume: 75 start-page: 47 year: 2017 ident: 655_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.01.009 – volume: 90 start-page: 638 issue: 3 year: 2016 ident: 655_CR4 publication-title: Kidney Int doi: 10.1016/j.kint.2016.04.008 – volume: 70 start-page: 581 issue: 4 year: 2017 ident: 655_CR10 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2017.04.026 – volume: 373 start-page: 23 issue: 1 year: 2015 ident: 655_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504030 – volume: 9 start-page: 411 issue: 3 year: 2016 ident: 655_CR8 publication-title: Clin Kidney J doi: 10.1093/ckj/sfw024 – volume: 69 start-page: 2251 issue: 12 year: 2006 ident: 655_CR11 publication-title: Kidney Int doi: 10.1038/sj.ki.5000341 – volume: 83 start-page: 142 year: 2017 ident: 655_CR14 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.06.020 – volume: 45 start-page: 7 year: 2016 ident: 655_CR5 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2016.02.003 – volume: 115 start-page: 1457 issue: 12 year: 2016 ident: 655_CR7 publication-title: Br J Cancer doi: 10.1038/bjc.2016.358 – volume: 67 start-page: 66 year: 2016 ident: 655_CR15 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.07.026 |
| SSID | ssj0001033888 |
| Score | 2.221832 |
| Snippet | Background
High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4... High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4... Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4... BackgroundHigh response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4... Abstract Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 181 |
| SubjectTerms | Abdomen Acute kidney failure Aged Antibodies Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Cancer Cancer metastasis Case Report Case Reports CAT scans Consent Creatinine Dehydrogenases Development and progression Disease Diuretics Dosage and administration Drug Substitution Drug therapy Edema Funding Humans Immune checkpoint inhibitors Immune-related adverse event Immunology Immunotherapy Ipilimumab Ipilimumab - administration & dosage Kidney diseases Kidney failure Kidney Function Tests Kidneys Lymphatic system Male Medical imaging Medical research Medicine Medicine & Public Health Melanoma Melanoma - complications Melanoma - diagnosis Melanoma - drug therapy Metastasis Microscopy Minimal change disease Molecular Targeted Therapy - adverse effects Monoclonal antibodies Nephritis Nephrotic syndrome Nephrotic Syndrome - diagnosis Nephrotic Syndrome - etiology Nivolumab Nivolumab - administration & dosage Oncology Oral drugs Patients PD-1 Pharmaceuticals Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Skin cancer Targeted cancer therapy Treatment Outcome Tumors Urine |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zj9MwELZgQYgX7iOwgJGQkEDWJo7r4wktx4oXVisEUt-i-AhE2k1K0yLx75lx3JYsYl94bDx27ZnP4xkfM4S8kE5jTBfJONeeCeEKphvXsJoXLoAJ2xQ2j8km1PGxns_NSdpwG9K1yo1OjIra9w73yA84AAVsAzAI3yx-MMwahaerKYXGZXIF02YjztVc7fZYcnDAtE6HmYWWB4NAkIL_jE_vZzMmJstRjNr_t27-Y3E6f3Hy3OlpXJSObv7vcG6RG8kcpYcjfm6TS6G7Q659Sgfud8nwebxDG-iqp9Ay-NHB03bRnrZn67Pa0rrztGujjsNfmHGc-t1FJNo3tKZdAMj08Bd0EyCBxjc00BQ0e_KeFRT6k96C_bpHvh59-PLuI0t5GphTeb5iYLR56YM2ngsL9poOIGVuQ-6VsLYIRlsbityVUtvGCD8zdSOD1NIYVwvVlPfJXtd34SGhM44BkbQyFj1PHYywwYOFqmRdGF3zjOQbcVUuBTHHXBqnVXRmtKxGCVcg4QolXImMvNpWWYwRPC4ifosY2BJi8O34oV9-q9JchqrccW9FbSQXTgbjjAdlLUrplAV3MiPPEEHV-JJ1q0Kqw5kpCwn2ZpGRl5EClQh039XpLQQwAcNxTSj3J5Qw-d20eAOvKimfodphKyPPt8VYEy_UdaFfAw2oaoVJisqMPBhBvR10iUecuQBmqAncJ1yZlnTt9xiaHDolgacZeb2ZGLtu_ZPpjy4exGNynccJq1jB98nearkOT8hV93PVDsunccb_BgqvW-s priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZbtQw0IKCUF-4oYECRkJCAlnEjuPYj-WoeKGqyqG-Wb5SIrVJtdlF4u8ZO8kuKYcEj1mPHWc8M57ZuRB6JpyMNV0EYUx6wrmjRNauJoZRF0CFranNU7OJ6uBAHh-rwzGPu5-i3SeXZJLUia2leNXzSF9g-sas-bIk_DK6AredjP0ajj5-2fyxkoPVJeXowfztzNkdlEr1_yqQf7qRLkZLXnCZppto_8Z_fcNNdH1UPPHeQCm30KXQ3kbXPoyu9TuoPxqiZQNedhhWA4s5eNycN6fN2erMWGxaj9smSbP4FHuLY78JOcJdjQ1uAxBHB6_AUykEnLJlYClY9vAtoRjofsz6-n4Xfd5_9-nNezJ2ZCCuyvMlAfXMCx-k8oxb0MxkgPNkNuS-4tbSoKS1geauENLWivtSmVoEIYVSzvCqLu6hrbZrww7CJYulj2SlbLQxZVDcBg-6aCUMVdKwDOXTGWk3liuPXTNOdTJbpNADMjUgU0dkap6hF-sp50Otjr8Bv44HvwaMZbbTD93iRI9cC1OZY95yowTjTgTllAexzAvhKguGY4aeRLLRQ87qWljovVIVVIBmSTP0PEFEcQHbd2bMegAkxMJbM8jdGSSwuZsPT6SpRzHTawbSE_YIVlKGnq6H48wYOteGbgUwIJSr2I6oyND9gZLXH11EZ2bOARnVjMZnWJmPtM3XVIQcNiUApxl6OVH6Zlt_RPqDf4J-iLZZYpWKULaLtpaLVXiErrpvy6ZfPE5c_wP-RFGE priority: 102 providerName: Springer Nature |
| Title | Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy |
| URI | https://link.springer.com/article/10.1186/s40425-019-0655-4 https://www.ncbi.nlm.nih.gov/pubmed/31300044 https://www.proquest.com/docview/2638112882 https://www.proquest.com/docview/2257706733 https://pubmed.ncbi.nlm.nih.gov/PMC6626404 https://doaj.org/article/112c2db4a9624c6e9c9d088436c7b259 |
| Volume | 7 |
| WOSCitedRecordID | wos000475646900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RBZ dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: BENPR dateStart: 20130501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Health and Medical Complete customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: 7X7 dateStart: 20130501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: PIMPY dateStart: 20130501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Journals customDbUrl: eissn: 2051-1426 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RSV dateStart: 20131201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_BQIgXxDeBUYyEhASKFjuuPx432AQPq6ryofFkxR8RkbZ0Wlsk_nvOTto1Q8ALL5EcXxL37nfnu9q-A3glnIo5XUTOmPI5547mqnZ1XjHqArqwNbVFKjYhJxN1cqKnW6W-4p6wLj1wx7g99Acc85ZXWjDuRNBOe9QMXgonLfru0foWUm8FU-nflQJDL6X6ZUyqxN6CR3hi5BwP3Y_HOR9MRClf_-9WeWtaurpl8sq6aZqOju7Cnd6PJPvd-O_BtdDeh1vH_Ur5A1jMus2vgSznBFGFAXDwpDlvTpuz1VllSdV60jbJOMVWLBVO_OUOIjKvSUXagLKe4yfIOrMBSYdf8FX42un7nBKEcX-I6-dD-HJ0-Pndh7wvsJA7WRTLHL0tL3xQ2jNu0dFSAcXDbCi85NbSoJW1gRauFMrWmvuxrmoRhBJau4rLunwEO-28DU-AjFnMZKSktjFkVEFzGzy6llJUVKuKZVCsuW1cn308FsE4NSkKUcJ0AjIoIBMFZHgGbzaPnHepN_5GfBBFuCGMWbPTDcSS6bFk_oWlDF5EAJjuCOpG983-WJdUoKNIM3idKKL24_Bd1R9iQCbEPFoDyt0BJWqtG3avQWZ6q7EwDI0hjhGDngxebrrjk3EnXBvmK6RBGytjdaEyg8cdJjc_uoxrkwVHZsgBWgdcGfa0zfeUUxwHJZCnGbxd4_pyWH9k-tP_wfRncJslrZQ5Zbuws7xYhedw0_1YNouLEVyXJzJd1QhuHBxOprNRUnVsTT8eT79ha_bp6y8Oc1OO |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3JbtQw1CoFARf2JVCokUBIRVETx-PlgFChVK3ajipUpLmZeAlEapNhFlB_im_k2UlmSBG99cBx4meP_fLW-C0IvWRG-JouLCZE2JhSk8aiMEWck9Q4MGGLVCeh2QQfDsVoJI9W0K8uF8aHVXYyMQhqWxv_jXyTAKGAbQAG4bvx99h3jfK3q10LjYYs9t3ZT3DZpm_3tuH9viJk5-Pxh9247SoQG54ksxhMDMusE9ISqsG6EA72RLRLLKdap04KrV2amIwJXUhqBzIvmGOCSWlyyosM1r2CroIc597Z4yO-_KaTgMMnRHt5mgq2OaWeKcBf96n-g0FMe-ovdAn4Wxf8oQzPB2qeu60NSnDn9v-GvjvoVmtu462GP-6iFVfdQ9cP24CC-2j6qYkRdnhWYziJhqcWl-PypDydn-Ya55XFVRlkuP_lO6pjuwy0wnWBc1w5YIka_gJ3BSBwyBGCpWDZo-04xXD-Ntft7AH6fClHfohWq7pyjxEeEF_wSXCpvWctnKTaWbDAOctTKXISoaQjD2XaIu2-V8iJCs6aYKqhKAUUpTxFKRqhjcWUcVOh5CLg957mFoC-uHh4UE--qlZWwVRiiNU0l4xQw5w00oIyohkzXIO7HKF1T7GqydRdiEi1NZBZysCeTiP0OkB4IQnbN3mb6wFI8OXGepBrPUgQbqY_3JGzaoXrVC1pOUIvFsN-pg8YrFw9BxhQRdw3Ycoi9KhhosWhM3-Fm1BABu-xVw8r_ZGq_BZKr8OmGOA0Qm86Rlxu659If3LxIdbRjd3jwwN1sDfcf4pukiAseJySNbQ6m8zdM3TN_JiV08nzIG0w-nLZ_Pkbzde59Q |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9Gh0aOKF-yUwmJFASKCoieM69gNCg1JRjVUVAmk8hfgSiLQlpRfQfo2v4ziXlgyxtz3w2PjYtU_ONT4XgCdcC1fThfuUCuMzpkNfZDrzUxpqiyZsFqqgajYRTybi6EhOt-BXmwvjwipbmVgJalNq9428T5FQ0DZAg7CfNWER0-Ho1ey77zpIuZvWtp1GTSIH9vQnum-Ll-MhvuunlI7efnzzzm86DPg6DoKlj-aG4cYKaShTaGkIi_ujygYmZkqFVgqlbBjoiAuVSWYGMs245YJLqVMWZxGuewm20SRntAfb0_Hh9PPmC0-A7p8QzVVqKHh_wRyLoPfuEv8HA591lGHVM-BvzfCHajwbtnnm7rZSiaNr_zMyr8PVxhAn-zXn3IAtW9yEncMm1OAWLD7U0cOWLEuCp1L41JB8lh_nJ6uTVJG0MKTIK-nufrle68RsQrBImZGUFBaZpcS_IG1pCFJlD-FSuOx06IcEz99kwZ3ehk8XcuQ70CvKwt4DMqCuFJSIpXI-t7CSKWvQNo95GkqRUg-CllQS3ZRvd11EjpPKjRM8qakrQepKHHUlzIPn6ymzunbJecCvHf2tAV3Z8epBOf-aNFIMp1JNjWKp5JRpbqWWBtUUi7iOFTrSHuw56k3qHN618Ez2BzIKOVraoQfPKggnPnH7Om2yQBAJrhBZB3K3A4liT3eHW9JOGrG7SDZ07cHj9bCb6UIJC1uuEAaVVOzaM0Ue3K0Zan3oyF3uBgyREXdYrYOV7kiRf6uKsuOmOOLUgxctU2629U-k3z__EHuwg2yZvB9PDh7AFVrJjdgP6S70lvOVfQiX9Y9lvpg_akQPgS8XzaC_AX0RxEQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Response+to+combined+ipilimumab+and+nivolumab+after+development+of+a+nephrotic+syndrome+related+to+PD-1+monotherapy&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Valerie+Glutsch&rft.au=Franziska+Gr%C3%A4n&rft.au=Judith+Weber&rft.au=Anja+Gesierich&rft.date=2019-07-12&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=7&rft.issue=1&rft.spage=1&rft.epage=5&rft_id=info:doi/10.1186%2Fs40425-019-0655-4&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_112c2db4a9624c6e9c9d088436c7b259 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |